The superior pathogen clearance observed in the Cp1-treated group relative to the CLP group may have resulted from the ability of Cp1 administration to effectively counteract sepsis-induced phagocytic impairment (particularly in neutrophils) mediated by excessive C5a. This evidence concerns the gene C5 and Sepsis.